AMPE - Ampio Pharma's Ampion reduces mortality nearly 80% in COVID-19

Ampio Pharmaceuticals ([[AMPE]] +4.8%) has revealed positive results from its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress due to COVID-19.All patients in the study have now completed treatment, including a follow-up at Day 28 after treatment.The study not only met its primary endpoint, the final data showed an even greater improvement in all-cause mortality over patients treated using Standard of Care ((SOC)).There was 78% improvement in all-cause mortality in SOC and Ampion treated group - 5%, compared to 24% in the SOC group.Preliminary results had been reported in March as 21% for SOC and 8% for Ampion, or a 62% improvement.Other findings from the study continue to show a positive outcome with Ampion treatment, including:The average hospital length of stay was 4 days less for the Ampion group compared to the patients receiving SOC.By day 5, 89% of patients who received Ampion were stable or

For further details see:

Ampio Pharma's Ampion reduces mortality nearly 80% in COVID-19